Kornimate/medical-research-clean huggingface dataset:
sorafenib versus best supportive care in egyptian hepatocellular carcinoma patients.

Conditions: HCC

Summary: the aim of the study is to evaluate the efficacy of sorafenib, compared to the best supportive care (bsc), in two cohorts of patients who presented with advanced hepatocellular carcinoma (hcc) based on etiology of hepatitis c virus.

in egypt, chronic hepatitis c virus (hcv) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. although hcv genotype 4 constitutes about 20% of hcv infections worldwide, the prevalence in egypt is more than 90%.(waked et al., 2016) in 2014 omar et al. reviewed 41 patients in a study to evaluate sorafenib for egyptian patients with advanced hepatocellular carcinoma at a median follow up period of 13 months, the median pfs for the whole group was 4 months; the median os for the whole group is 6.25 months.(abdel-rahman et al., 2014) till current, no studies have evaluated the sorafenib efficacy in comparison to the best supportive care treatment in hcc patients whose etiology from hcv genotype 4 ( the most prevalent hepatitis c virus genotype in egypt). so, the study aims to evaluate the efficacy of sorafenib, compared to the best supportive care (bsc), in two cohorts of patients who presented with advanced hepatocellular carcinoma (hcc) based on etiology of hepatitis c virus.

Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age 2. patients based on etiology of hepatitis c virus. 3. eastern cooperative oncology group (ecog) performance status score of 2 or less 4. child-pugh liver function class a,b 5. a life expectancy of 12 weeks or more 6. adequate hematologic function (platelet count, ≥60×109 per liter; hemoglobin, ≥8.5 g per deciliter; and prothrombin time international normalized ratio, ≤2.3; or prothrombin time, ≤6 seconds above control), adequate hepatic function (albumin, ≥2.8 g per deciliter; total bilirubin, ≤3 mg per deciliter \[51.3 µmol per liter\]; and alanine aminotransferase and aspartate aminotransferase, ≤5 times the upper limit of the normal range), and adequate renal function (serum creatinine, ≤1.5 times the upper limit of the normal range). 7. patients were required to have at least one untreated target lesion that could be measured in one dimension, according to the response evaluation criteria in solid tumors (recist) exclusion criteria: 1. had previously received molecularly targeted therapies or any other systemic treatment. 2. any co morbid disease that will confuse the assessment of the quality of life questionnaire scorefhsi-8 score.
randomized comparison angioplasty outcomes at hospitals with and without on-site cardiac surgery

Conditions: Coronary Arteriosclerosis; Angina Pectoris

Summary: angioplasty is a procedure which opens blocked heart arteries using balloons and/or stents. most u.s. states and all national heart organizations require that angioplasty be done only at hospitals that can also perform open heart surgery. the reason for this is that there is a risk that angioplasty can cause injury to the heart artery that might require open heart surgery to fix. open heart surgery is a backup in case it is needed. the risk that open heart surgery will be needed is very small. nevertheless, without more research, many state departments of health and all national heart organizations do not want to change the requirement for having on-site open heart surgery wherever angioplasty is performed. some states already allow this; and european heart organizations already allow it, as well. this study is designed to determine whether the safety and benefits of angioplasty are the same at hospitals that perform angioplasty either with or without open heart surgery backup. patient who enter the study have a heart catheterization at a hospital without a heart surgery program. if they need angioplasty, then they are randomized to either stay at the hospital without heart surgery for their angioplasty or to be transferred for the procedure to a hospital with heart surgery. for every four patients, three stay at the hospital without heart surgery and one is transferred. the study is designed to show that there is no detectable difference between the safety and benefits of the procedure at the two types of hospital (with and without heart surgery). the cost of the procedure at the two hospital types is also compared.


Eligibility criteria:
inclusion criteria: pre-catheterization: * must be undergoing diagnostic cardiac catheterization for suspected cad * be at least 18 years of age * must not be pregnant (negative pregnancy test) or must not be of childbearing potential must be able to give informed consent. post-catheterization: * coronary artery disease judged to be clinically and angiographically significant * ability to perform pci with equipment available at the local site * procedure risk judged to be not high (see below) exclusion criteria: pre-catheterization: * inability to give informed consent * st-segment elevation myocardial infarction * pregnancy post-catheterization: * high likelihood of requiring a device not available at the hospitals without sos * no need for pci * need for coronary artery bypass surgery * high procedural risk (see below) high procedural risk criteria are: * pci of unprotected left main coronary artery * pci of left circulation lesion in the presence of critical (\>70%) unprotected left main coronary artery lesion * poor left ventricular function (ef\< 20%) and need to perform pci in a vessel supplying significant myocardium

Keywords: coronary artery disease angioplasty stent percutaneous coronary intervention on-site cardiac surgery randomized trial
the effect of different feeding methods on infants

Conditions: Preterm Infants; Injector; Finger; Sucking Success; Nursing Caries

Summary: objective: the aim of this study was to investigate the effect of finger feeding and syringe feeding methods on infant weight, time to full oral feeding and breastfeeding success in preterm infants. h01: there is no difference between the weights of preterm babies fed by finger and by syringe. h02: there is no difference in the transition time between finger-fed and syringe-fed preterm babies to full oral feeding. h03: there is no difference between breastfeeding success between finger and syringe feeding methods.

the study was conducted as a parallel groups randomized experimental study. the study was conducted between december 1, 2021 and june 1, 2023 in the neonatal intensive care unit of aydın obstetrics and gynecology hospital. the sample included preterm infants with 320/7-366/7 gestation weeks who were receiving care and treatment in the neonatal intensive care unit. in the sample, n=38 infants were randomly assigned to study group 1 and n=36 infants to study group 2 and the study was completed with n=74 infants. the data were collected using the preterm infant information form, preterm infant follow-up form and latch breastfeeding diagnostic measurement tool. the babies selected for the study group were fed with the method of whichever study group they were added to (finger or syringe feeding) at three feeding meals each day. after switching to full oral feeding, breastfeeding success was measured with the breastfeeding diagnostic measurement tool (latch), which was used when the infants first held the breast and the time of transition to full oral feeding. the difference between groups was analyzed using mann whitney u analysis for non-normally distributed data and the difference between groups for normally distributed data was analyzed using independent two sample t test. homogeneity of variances was assessed by levene's test. since the standard error indicates the spread of the means of the samples selected from the same population and the standard deviation indicates the distance of each individual in the group from the mean, the standard error values were given together with the means in the analyses comparing the group means.

Eligibility criteria:
inclusion criteria: * having a gestational age between 32 weeks and 36+6 weeks, * weighing 1500 g or more, * having spontaneous breathing (can receive free oxygen, incubator oxygen), * those who have been fed only by gavage or parenterally and are ready to switch to oral feeding, * preterm babies whose parents were literate in turkish and gave consent were included in the study. exclusion criteria: * those who were fed orally before the research, * those who need noninvasive mechanical ventilation such as cpap, * babies with metabolic diseases were excluded from the study.
stem cell transplantation for patients with multiple myeloma

Conditions: Myeloma

Summary: the purpose of this study is to test whether regulatory t-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (asct).


Eligibility criteria:
inclusion criteria: * symptomatic multiple myeloma of any subtype in any disease stage, providing that patient does not have smoldering myeloma. * patient must otherwise be a candidate for asct as determined by treating physician. * no current cns myeloma at time of enrollment. * life expectancy greater than 12 weeks. * age greater than or equal to 21 and less than or equal to 70 years old. * egog performance status less than or equal to 2. * no cardiac, pulmonary, hepatic, or renal contraindications for high dose chemotherapy. * hiv negative. * no active hepatitis b or c. * patients must be able to provide written informed, consent. exclusion criteria: * pregnant or nursing women. women of child-bearing age must be tested for pregnancy. * use of systemic immunosuppressive medications, including corticosteroids, tacrolimus, mycophenolate mofetil, sirolimus or cyclosporine a. * psychiatric illness which may make compliance to the clinical protocol unmanageable or which may compromise the ability of the patient to give informed consent. * active autoimmune disease including but not limited to: rheumatoid arthritis inflammatory bowel disease, celiac disease, systemic lupus erythematosis, scleroderma or multiple sclerosis.
tchcct-zhong-xing-emergency-department-airway-clincal (ttc)

Conditions: Intubation;Difficult; Intubation Complication

Summary: in the previous study on mannekin, the investigators found stylet-assisted lifting of epiglottis is an useful technique on difficult airway (cormack-lehane grade iiia, iiib) without increasing subjective difficulty. it has no expenses other than the routine intubation process. recently, the studies have proved that the bougie-assisted laryngoscopy can improve first pass intubation rate in the emergency department. however, bougie is a disposable device and may increased medical expenditure. the investigators will evaluate the safety of bougie and epiglottic lifting technique, as well as the first pass and overall success rate of intubation comparing to traditional video laryngoscopy and direct laryngoscopy.

a better strategy of managing cormack-lehane grade iii had been investigated by our previous study. the investigators' research results had been accepted and published by the journal biomeidcal central anesthesiology. the investigators will be eager to do the further clinical trial to investigate the impact of this technique clinically. besides, bougie assisted intubation is a effective, evidenced-proved intervention. the investigators will also like to find out the prognosis differences between these two techniques.

Eligibility criteria:
inclusion criteria: * all the patients present to the emergency department with airway emergency who need intubation exclusion criteria: * age below 18 year-old
contralaterally controlled functional electrical stimulation plus video games for hand therapy after stroke

Conditions: Upper Extremity Hemiplegia; Stroke

Summary: determine if adding a video game component to an electrical stimulation therapy improves hand function in stroke patients

a single-blinded randomized controlled trial will be carried out to assess the effects of 12 weeks of contralaterally controlled functional electrical stimulation (ccfes) +hand therapy video games (htvg) compared to ccfes. dexterity and activity limitation will be assessed at 0 (baseline), 12 (end of treatment), and 36 (6 months follow-up) wks. the planned treatment dose will be the same for both groups: 10 sessions per week of self-administered treatment at home plus 20 sessions of group-specific occupational therapy in the lab over 12 weeks.

Eligibility criteria:
inclusion criteria: -\> 6 months since a first clinical cortical or subcortical, hemorrhagic or nonhemorrhagic stroke * age 21-80 years old * unilateral upper limb hemiparesis with finger extensor strength of grade \ =1 and \<=11/14 on the hand section of the upper extremity fugl-meyer assessment * adequate active movement of the shoulder and elbow to position the hand in the workspace for table-top task practice (necessary for the lab task practice sessions) * able to follow 3-stage commands * able to recall 2 of 3 words after 30 minutes * surface stimulation of the paretic finger and thumb extensors produces functional hand opening without pain (this will exclude those who have degree of flexor hypertonia that prevents stimulated hand opening) * functional passive range of motion (minimal resistance) at elbow, wrist, fingers, and thumb, i.e., there exists enough passive range of motion to reach and acquire table-top objects * intact vision and hearing * medically stable * full voluntary opening/closing of the contralateral (less affected) hand * demonstrate ability to follow instructions for operating the stimulator or have a caregiver who will assist them exclusion criteria: * co-existing neurologic diagnosis of peripheral nerve injury, parkinson's disease, spinal cord injury, traumatic brain injury, or multiple sclerosis * uncontrolled seizure disorder * severely impaired cognition and communication * uncompensated hemineglect * arm or forearm skin breakdown or edema (to avoid edema-related shunting of current) * insensate forearm (to avoid risk of electrical burns) * history of potentially fatal cardiac arrhythmias with hemodynamic instability * implanted electronic systems (e.g. pacemaker) * botulinum toxin injections to any upper extremity muscle within 3 months of enrolling * pregnant women due to unknown risks of surface stimulation during pregnancy * participating in occupational therapy or other rehabilitation therapies to the upper extremity * severe shoulder or hand pain

Keywords: stroke rehabilitation hemiplegia
postoperative hip bracing after hip arthroscopy

Conditions: Femoroacetabular Impingement Syndrome; Acetabular Labral Tear

Summary: hip arthroscopy for treatment of femoroacetabular impingement syndrome (fais) involves reshaping of the osseous sources of impingement ("osteoplasty") and treatment of impingement-associated labral tears with labral repair. postoperative hip braces are advocated to decrease postoperative pain by offloading hip musculature. however there are no studies looking at efficacy of hip braces after hip arthroscopy, and on average 50% of high-volume hip arthroscopists use bracing. the objective of this study is to use a randomized controlled trial to test the cited benefits of postoperative hip bracing on short term patient reported pain scores, validated hip-specific pain scores, and physical exam findings of hip flexor tendonitis.

hip arthroscopy for treatment of femoroacetabular impingement syndrome (fais) involves reshaping of the osseous sources of impingement ("osteoplasty") and treatment of impingement-associated labral tears with labral repair. the hip joint is subluxated with traction to accomplish this procedure. the diagnoses of fais and the incidence of hip arthroscopy have both increased dramatically in the last 20 years in the us -- in a recent study using ibm marketscan to evaluate rates of hip arthroscopic treatment of fais, the investigators found this incidence doubled from 1.2 to 2.1 per 100,000 person-years in just a 3-year period. despite the increasing incidence of hip arthroscopy in the us, on a recent review the investigators have found few evidence-based studies on postoperative care. a particular area of debate is the use of postoperative hip braces. postoperative hip braces are advocated to decrease postoperative pain by offloading hip musculature. they may also prevent overuse of the hip flexors by supporting the hip during gait. however there are no studies looking at efficacy of hip braces after hip arthroscopy, and on average 50% of high-volume hip arthroscopists use bracing. the utility of bracing is important because hip braces are expensive (averaging $350-$600): if there are over 7000 hip arthroscopies performed nationwide and 50% of surgeons use hip braces, this amounts to over $2,000,000. the investigator's overall objective is to use a randomized controlled trial to test the cited benefits of postoperative hip bracing on short term patient reported pain scores, validated hip-specific pain scores, and physical exam findings of hip flexor tendonitis.

Eligibility criteria:
inclusion criteria: * patient age 14-60 on date of surgery * patient seen at the institution for the study * patient scheduled to undergo arthroscopic osteoplasty and labral repair for femoroacetabular impingement syndrome. exclusion criteria: * any patient anyone who cannot follow up in person in clinic for the 6-week postoperative visit. * non-english speaking patients (due to limited validation of the patient reported outcome measures in non-english speaking populations).
effects of tiotropium on breathing capacity and exercise limitation in early stages of chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: optimal clinical management in early stages of copd is not established. tiotropium has been shown to improve exercise tolerance during (cwr) cycle ergometry with gold stage ii to iv copd, improvements in constant speed treadmill time in a study of patients who also received pulmonary rehabilitation in a population of patients with predominantly severe and very severe disease (gold stages iii and iv) and improvements in exertional dyspnea, and shuttle walk test distance in gold stage iii and iv copd. however, data are lacking on the benefits of tiotropium on exercise tolerance in a patients with early stages of copd who are symptomatic. patients with milder ventilatory limitations (gold stages i/ii copd patients) may benefit from maintenance therapy and there is limited data on exercise limitation in patients with early stage copd who are symptomatic. this study is designed to evaluate the mechanisms of breathlessness and assess physical activity limitation in early stage copd patients compared to age and gender matched controls and will secondly investigate the effectiveness of treatment with tiotropium in improving dyspnea during exercise and exercise duration as a result of the bronchodilation effects of tiotropium leading to a reduction of dynamic hyperinflation in early stage copd patients.


Eligibility criteria:
inclusion criteria: for copd subjects: male or female, age of 40 years or older, smoking history \>10 pack-years, symptomatic defined as baseline dyspnea index focal score of 9 or more and / or daily cough with production of sputum for three months per year during at least two consecutive years, diagnosis of early stage copd according to: post-bronchodilator fev1/fvc ratio \ /=50% post-bronchodilator predicted normal, and a decreased inspiratory capacity during exercise. for age / gender matched controls: male or female, age of 40 years or older, nonsmoker, with no significant diseases. exclusion criteria: patients with a significant disease other than copd; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study. patients with a history of asthma, patients requiring the use of supplemental oxygen therapy, patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris, claudication or other conditions, or patients with contraindications to exercise. note: additional exclusion criteria for age / gender matched controls: patients with a significant disease including copd.
study to investigate the efficacy of abrocitinib in adult participants with severe fatigue from post covid condition/long covid

Conditions: Post-COVID Condition; Fatigue Symptom

Summary: the primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic post-covid condition (pcc) (also called long covid). we are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from pcc. eligible participants with a confirmed history of covid19 infection who also have pcc according to the world health organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).

eligible volunteers will participate in six in-person visits over 4 months. these visits include review of medical and medication history, answering questionnaires, blood, urine, and nasal swab specimen collection, physical exams, and contraceptive and medication counseling.

Eligibility criteria:
inclusion criteria: * history of confirmed covid-19 infection * pcc diagnosis according to the who definition as occurring in individuals with a history of probable or confirmed sars cov-2 infection, usually 3 months from the onset of covid-19 that lasts for at least 2 months and cannot be explained by an alternative diagnosis * participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures * capable of giving signed informed consent exclusion criteria: * participants with acute and chronic infections, history of specific recurrent infections * suspected or confirmed active sars-cov-2 infection within past 30 days * some cardiac conditions * current or former tobacco smoker within the last 12 months * known to be infected with human immunodeficiency virus (hiv), hepatitis b, or hepatitis c, herpes virus, or tuberculosis * history of immunodeficiency * blood clotting conditions * must meet general screening laboratory criteria * allergy or other contraindication to any of the components of the study intervention * known prior participation in this trial or other trial involving abrocitinib * concurrent therapy with a jak or tyk2 inhibitor * other protocol criteria apply

Keywords: long covid post-covid condition pcc fatigue